AstraZeneca has recently announced the release of Andaishi& Reg; (Common name: Daggligin Metformin Sustained Release Tablets) This compound preparation for type 2 diabetes is marketed in China. It is reported that, as the only compound preparation of SGLT2 inhibitor and metformin hydrochloride sustained-release agent that takes a fixed dose once a day in China, daggligin metformin sustained-release tablets provide a first-line treatment option for improving blood glucose control in patients with type 2 diabetes.
The Guidelines for the Prevention and Treatment of Type 2 diabetes in China (2020 Edition) points out that the short-term goal of diabetes treatment is to eliminate the symptoms of diabetes and prevent acute complications by controlling hyperglycemia and metabolic disorders, and the long-term goal is to prevent cardiorenal complications, improve the quality of life of patients and extend life through good metabolic control.
Professor Ji Linong, from Peking University People's Hospital, said that the arrival of daggligin metformin sustained-release tablets provided a new treatment method of "one scheme, double protection" for the achievement of short-term and long-term goals of diabetes treatment.
Professor Zou Dajin from Tongren Hospital affiliated with Shanghai Jiao Tong University School of Medicine believes that the two complementary mechanisms of action of Daggliflozin metformin sustained-release tablets help simplify treatment plans and improve patient treatment compliance.
Lai Minglong, general manager of AstraZeneca China, said that improving blood glucose control rate and reducing heart and kidney complications are important tasks for the prevention and treatment of diabetes in China, and hoped that the application of daggligin metformin sustained-release tablets would be accelerated in China.
Wen/Guangzhou Daily · New Flower City Reporter Tu Duanyu